HOOK News and Press, HOOKIPA Pharma Inc. From 12/31/20

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform. Hookipa has an infectious disease/oncology pipeline of six therapeutics. including three in clinical trials including HB-101 f...

NEW YORK and VIENNA, Austria, Dec. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the closing of its previously announced underwritten public offering of an...

HOOKIPA Pharma (HOOK) has priced an underwritten public offering of 3.4M common shares at $11.75/share and 2,978 shares of its Series A convertible preferred stock at $11,750/share (each share of Series A preferred stock is convertible into 1,000 shares of common...

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 3,400,000 shares of its ...

HOOKIPA Pharma (HOOK) intends to offer and sell shares of its common stock and shares of Series A convertible preferred stock in an underwritten public offering.Underwriters granted a 30-day option to purchase up to an additional 15% of the shares.Shares -4.6% AH. For further deta...

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it intends to offer and sell shares of its common stock and shar...

Results support first proof of concept for HOOKIPA’s replicating investigational single-vector immunotherapy in oncology Data demonstrate responses and stable disease in some head and neck cancer patients who all received at least two prior therapies and progressed on a PD1...

Hookipa (HOOK) announces positive interim data from a Phase 2 clinical trial evaluating cytomegalovirus ((CMV)) vaccine candidate HB-101 in patients receiving a transplanted kidney from a live donor.41 CMV-negative patients were evaluated for CMV-neutralizing antibody titers to...

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease Observed CMV-neutralizing antibody responses and tolerability profile are consis...

HOOKIPA Pharma (HOOK): Q3 GAAP EPS of -$0.53 misses by $0.09.Revenue of $4.04M (+98.0% Y/Y) misses by $0.58M.Press Release For further details see: HOOKIPA Pharma EPS misses by $0.09, misses on revenue